Shares shifted violently upward as Picard Medical, the maker of the world's only FDA-approved total artificial heart, delivered a quarter that blindsided the Street. The stock has surged roughly 75% in two sessions — from $3.03 on August 20 to $5.68 today — after Q2 revenue nearly doubled what analysts expected. But behind the headline beat sits a company with $38,000 in cash, deep losses, and a recent 1-for-50 reverse stock split just to keep its exchange listing. The question is whether revenue momentum can outrun a precarious balance sheet.

  • Revenue Crushed Estimates, but the Bar Was Extremely Low

Q2 revenue of $2.95 million surpassed estimates by roughly 91%, with a 39% year-over-year increase and a positive gross margin of 20.9%.

That compares with a negative 6% gross margin a year earlier. Impressive progress — but context matters. Full-year 2025 revenue was just $4.94 million. In six months, Picard has already posted $4.1 million, a 50% jump. The trajectory is real, but the total revenue base is still tiny by any medical-device standard.

  • The Company Is Nearly Out of Cash

As of June 30, 2026, Picard held just $38,000 in cash against $7.5 million in total current liabilities.

Management has acknowledged that additional capital will be required to support operations.

Trailing twelve-month operating cash flow was negative $16 million. That means even with better sales, the company will almost certainly need to raise money — likely by selling new shares, which dilutes existing holders.

  • Losses Still Dwarf Revenue

The income statement shows ~$2.95 million in quarterly revenue, but EBIT margins run around -443% — meaning the company lost more than four dollars for every dollar it sold. Net loss was ~$5.7 million in Q2, down 16% from a year ago but still nearly double the quarter's revenue.

  • A Reverse Split and Listing Risk Lurk in the Background

On July 22, Picard executed a 1-for-50 reverse stock split to comply with NYSE American listing requirements.

The exchange granted a compliance window through November 2027 , but that clock is ticking. Shares outstanding have ballooned by over 800% in one year , a clear sign of heavy dilution from past fundraising.

The revenue beat is genuine and shows the artificial heart is gaining traction in U.S. hospitals. But investors chasing this rally are betting that growth can accelerate fast enough to close a yawning gap between sales and cash burn before the next capital raise arrives.